Methods for predicting psychotropic drugs which elicit weight gain
View Patent ↗The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
1. A method of predicting whether an agent which is a psychotropic drug or a candidate psychotropic drug will be orexigenic, comprising the steps of:
(i) contacting the agent in vitro with a histamine H 1 receptor (H1R) and determining if the agent binds to the H1R or contacting the agent in vitro with a histamine H 1 receptor (H1R) in the presence of histamine and determining if the agent inhibits histamine binding to the H1R by comparison to a control with no agent;
(ii) contacting the agent in vitro with a hypothalamic adenosine monophosphate kinase (AMPK) and determining if the agent increases phosphorylation or increases activity of the AMPK by comparison to a control with no agent present; and
(iii) identifying the agent as likely to be orexigenic when it both (a) binds to H1R or inhibits histamine binding to H1R, and (b) increases phosphorylation of hypothalamic AMPK or increases hypothalamic AMPK activity.
2. The method of claim 1 wherein the step of contacting the agent with a hypothalamic AMPK is performed in the presence of leptin or insulin.
3. The method of claim 1 wherein the agent is an anti-depressant drug or candidate anti-depressant drug.
4. The method of claim 1 wherein the agent is an anti-psychotic drug or candidate anti- psychotic drug.
5. The method of claim 1 wherein the hypothalamic AMPK is in a hypothalamus tissue slice.
6. The method of claim 1 wherein the hypothalamic AMPK is in a hypothalamus cell line.
7. The method of claim 1 wherein the H1R is in a crude mammalian brain membrane preparation.
8. The method of claim 1 wherein the H1R is a cloned, human H1R.
9. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) and the binding of the agent to the H1R is determined.
10. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) in the presence of histamine and the inhibition of histamine binding to H1R is determined.
11. The method of claim 1 wherein the agent is contacted with a hypothalamic AMPK and an increase in AMPK phosphorylation is determined.
12. The method of claim 1 wherein the agent is contacted with a hypothalamic AMPK and an increase in AMPK activity is determined.
13. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) and the binding of the agent to the H1R is determined and the agent is contacted with a hypothalamic AMPK and an increase in AMPK phosphorylation is determined.
14. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) and the binding of the agent to the H1R is determined and the agent is contacted with a hypothalamic AMPK and an increase in AMPK activity is determined.
15. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) in the presence of histamine and the inhibition of histamine binding to H1R is determined and the agent is contacted with a hypothalamic AMPK and an increase in AMPK phosphorylation is determined.
16. The method of claim 1 wherein the agent is contacted with a histamine H 1 receptor (H1R) in the presence of histamine and the inhibition of histamine binding to H1R is determined and the agent is contacted with a hypothalamic AMPK and an increase in AMPK activity is determined.